Deal Watch: Bristol Continues Push Into Fibrotic Disease Area
Executive Summary
Novartis and Amgen exchange rights around CNS candidates in Alzheimer’s and migraine. AstraZeneca out-licenses global rights, except for Japan and Asia, for Phase III psoriasis candidate brodalumab to Valeant.
You may also be interested in...
Bristol’s Fibrotic Game Plan: Promedior Acquisition Hinges On Phase II Results
Bristol’s third deal in anti-fibrosis field in past year could give it intravenous, disease-modifying candidate for myelofibrosis and idiopathic fibrosis.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.